Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mohd Danish Ansari, Hozeyfa Sagir, Vijay B. Yadav, Ankit Verma, Mohd Nazeef, Sonam Shakya & I. R. Siddiqui. (2023) DFT Analysis and Synthesis of Medicinally Important Pyrrolo[2,3-d]Pyrimidines by Using Thiamine Hydrochloride as a Recyclable Organocatalyst in Aqueous Media. Polycyclic Aromatic Compounds 43:8, pages 7531-7546.
Read now
Read now
Steve Wenglowsky. (2013) Pyrazolo[3,4-b]pyridine kinase inhibitors: a patent review (2008 – present). Expert Opinion on Therapeutic Patents 23:3, pages 281-298.
Read now
Read now
Articles from other publishers (42)
Shoaib Khan, Krishna Mohan, Sazina Muzammil, Md. Aftab Alam & Khalid Umer Khayyam. (2024) Current Prospects in Rheumatoid Arthritis: Pathophysiology,
Genetics, and Treatments. Recent Advances in Anti-Infective Drug Discovery 19:1, pages 36-55.
Crossref
Crossref
Pooja Mathur, Ravinder Verma, Manish Kumar, Vikas Jhawat, Rohit Dutt & Shailendra Bhatt. (2023) Current Remedial Strategies for the Treatment of Rheumatoid Arthritis
through the Oral Route with Janus Kinase Inhibitors. Drug Delivery Letters 13:1, pages 13-23.
Crossref
Crossref
Zhiqing Xu & Ming Chu. (2022) Advances in Immunosuppressive Agents Based on Signal Pathway. Frontiers in Pharmacology 13.
Crossref
Crossref
Reza Elahi, Parsa Karami, Amir Hossein Heidary & Abdolreza Esmaeilzadeh. (2022) An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19). International Immunopharmacology 105, pages 108536.
Crossref
Crossref
Sara Assadiasl, Yousef Fatahi, Banafsheh Mosharmovahed, Bahareh Mohebbi & Mohammad Hossein Nicknam. (2021) Baricitinib: From Rheumatoid Arthritis to COVID‐19. The Journal of Clinical Pharmacology 61:10, pages 1274-1285.
Crossref
Crossref
Aliza Paudyal, Ming Zheng, Ling Lyu, Christina Thapa, Shirui Gong, Yao Yang & Xiaoyan Lyu. (2021)
JAK‐inhibitors
for dermatomyositis: A concise literature review
. Dermatologic Therapy 34:3.
Crossref
Crossref
Arezoo Hosseini, Tohid Gharibi, Faroogh Marofi, Mahsa Javadian, Zohreh Babaloo & Behzad Baradaran. (2020) Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. Journal of Cellular Physiology 235:9, pages 5903-5924.
Crossref
Crossref
Seffens, Herrera, Tegla, Buus, Hymes, Ødum, Geskin & Koralov. (2019) STAT3 Dysregulation in Mature T and NK Cell Lymphomas. Cancers 11:11, pages 1711.
Crossref
Crossref
Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin, Yanlei Zhang, Steven Spergel, James Kempson, John S. Tokarski, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, David Shuster, Kathleen Gillooly, Xiaoxia Yang, Elizabeth Heimrich, Kim W. McIntyre, Charu Chaudhry, Javed Khan, Max Ruzanov, Jeffrey Tredup, Dawn Mulligan, Dianlin Xie, Huadong Sun, Christine Huang, Celia D’Arienzo, Nelly Aranibar, Manoj Chiney, Anjaneya Chimalakonda, William J. Pitts, Louis Lombardo, Percy H. Carter, James R. Burke & David S. Weinstein. (2019) Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. Journal of Medicinal Chemistry 62:20, pages 8973-8995.
Crossref
Crossref
Hua-Qiang Sun, Dong Yan, Qin-Nan Wang, Hong-Zheng Meng, Ye-Yong Zhang, Lu-Xu Yin, Xin-Feng Yan & Shu-Feng Li. (2018) 1,25-Dihydroxyvitamin D3 attenuates disease severity and induces synoviocyte apoptosis in a concentration-dependent manner in rats with adjuvant-induced arthritis by inactivating the NF-κB signaling pathway. Journal of Bone and Mineral Metabolism 37:3, pages 430-440.
Crossref
Crossref
Thilo J. Heckrodt, Yan Chen & Rajinder Singh. (2019) Synthesis of the isotopically labeled JAK1/3 inhibitor [D]-R545 and its oxidative metabolite [D]-R935: Protecting group-directed regioselective bromination to access 3,4,5-substituted anilines. Tetrahedron 75:16, pages 2385-2399.
Crossref
Crossref
Raheel Zubair, Alexis B. Lyons, Gautham Vellaichamy, Anjelica Peacock & Iltefat Hamzavi. (2019) What’s New in Pigmentary Disorders. Dermatologic Clinics 37:2, pages 175-181.
Crossref
Crossref
Marian C. Bryan & Naomi S. Rajapaksa. (2018) Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. Journal of Medicinal Chemistry 61:20, pages 9030-9058.
Crossref
Crossref
Andrea B.V. Lomonte, Sebastião C. Radominski, Flora M.D. Marcolino, Claiton V. Brenol, Cristiano A.F. Zerbini, Erika G. García, Ermeg L. Akylbekova, Ricardo Rojo & Dario Ponce de Leon. (2018) Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis. Medicine 97:31, pages e11609.
Crossref
Crossref
Charles J. Malemud. (2018) The role of the JAK/STAT signal pathway in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 10:5-6, pages 117-127.
Crossref
Crossref
Vijay B. Yadav, Pragati Rai, Hozeyfa Sagir, Akhilesh Kumar & I. R. Siddiqui. (2018)
A green route for the synthesis of pyrrolo[2,3-
d
]pyrimidine derivatives catalyzed by β-cyclodextrin
. New Journal of Chemistry 42:1, pages 628-633.
Crossref
Crossref
Shubhasree Banerjee, Ann Biehl, Massimo Gadina, Sarfaraz Hasni & Daniella M. Schwartz. (2017) JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs 77:5, pages 521-546.
Crossref
Crossref
Jing Li Wang, Li Ping Cheng, Tian Chi Wang, Wei Deng & Fan Hong Wu. (2017) Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques. Journal of Molecular Graphics and Modelling 72, pages 178-186.
Crossref
Crossref
Shaik Karamthulla, Asim Jana & Lokman H. Choudhury. (2017)
Synthesis of Novel 5,6-Disubstituted Pyrrolo [2,3-
d
]Pyrimidine-2,4-Diones Via One-Pot Three-Component Reactions
. ACS Combinatorial Science 19:2, pages 108-112.
Crossref
Crossref
C. A. F. Zerbini, P. Clark, L. Mendez-Sanchez, R. M. R. Pereira, O. D. Messina, C. R. Uña, J. D. Adachi, W. F. Lems, C. Cooper & N. E. Lane. (2016) Biologic therapies and bone loss in rheumatoid arthritis. Osteoporosis International 28:2, pages 429-446.
Crossref
Crossref
Ruben Vardanyan. 2017. Piperidine-Based Drug Discovery. Piperidine-Based Drug Discovery
127
146
.
Jelena Todoric, Laura Antonucci & Michael Karin. (2016) Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prevention Research 9:12, pages 895-905.
Crossref
Crossref
Junru Liu, Juan Li, Meilan Chen & Lifen Kuang. (2016) Bortezomib followed by autologous stem cell transplantation in a patient with rheumatoid arthritis. Medicine 95:52, pages e5760.
Crossref
Crossref
Mohamed-Eslam F. Mohamed, Heidi S. Camp, Ping Jiang, Robert J. Padley, Armen Asatryan & Ahmed A. Othman. (2016) Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. Clinical Pharmacokinetics 55:12, pages 1547-1558.
Crossref
Crossref
Vladimir Simov, Sujal V. Deshmukh, Christopher J. Dinsmore, Fiona Elwood, Rafael B. Fernandez, Yudith Garcia, Craig Gibeau, Hakan Gunaydin, Joon Jung, Jason D. Katz, Brian Kraybill, Blair Lapointe, Sangita B. Patel, Tony Siu, Hua Su & Jonathan R. Young. (2016) Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 26:7, pages 1803-1808.
Crossref
Crossref
Suzanne J. Tintle & Alice B. Gottlieb. (2015) Psoriatic Arthritis for the Dermatologist. Dermatologic Clinics 33:1, pages 127-148.
Crossref
Crossref
David Wojciechowski & Flavio Vincenti. 2015. Transplantation of the Liver. Transplantation of the Liver
1332
1342
.
Eva Salgado & José Ramón Maneiro. (2014) Nuevos tratamientos en artritis reumatoide. Medicina Clínica 143:10, pages 461-466.
Crossref
Crossref
Christopher Chang. (2014) Unmet needs in the treatment of autoimmunity: From aspirin to stem cells. Autoimmunity Reviews 13:4-5, pages 331-346.
Crossref
Crossref
Matthias Gehringer, Ellen Pfaffenrot, Silke Bauer & Stefan A. Laufer. (2014) Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes. ChemMedChem 9:2, pages 277-281.
Crossref
Crossref
Kh. Dhanachandra Singh, Queen Naveena & Muthusamy Karthikeyan. (2014) Jak2 inhibitor – a jackpot for pharmaceutical industries: a comprehensive computational method in the discovery of new potent Jak2 inhibitors. Mol. BioSyst. 10:8, pages 2146-2159.
Crossref
Crossref
Edward Keystone & Marc D. Cohen. (2013) Cell-Signaling Therapy in Rheumatoid Arthritis. Current Rheumatology Reports 15:10.
Crossref
Crossref
Paweł Kawalec, Alicja Mikrut, Natalia Wiśniewska & Andrzej Pilc. (2013) The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clinical Rheumatology 32:10, pages 1415-1424.
Crossref
Crossref
Teun van Gelder, Carla Baan, Flavio Vincenti & Roslyn B. Mannon. (2013) Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma. Transplant International 26:9, pages 938-948.
Crossref
Crossref
Han Ni, Soe Moe, Kay Thi Myint & Aung Htet. (2013) Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib. ISRN Rheumatology 2013, pages 1-9.
Crossref
Crossref
Martin S. Zand. (2013) Tofacitinab in Renal Transplantation. Transplantation Reviews 27:3, pages 85-89.
Crossref
Crossref
Matthias Gehringer, Michael Forster, Dieter Schollmeyer & Stefan Laufer. (2013)
tert
-Butyl
N
-[(3
R
,4
R
)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl]-
N
-methylcarbamate
. Acta Crystallographica Section E Structure Reports Online 69:6, pages o935-o935.
Crossref
Crossref
Maria Angeles Lopez-Olivo, Mahesh Bavineni & Maria E Suarez-Almazor. (2013) Tofacitinib for rheumatoid arthritis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Piotr P Graczyk. (2013) JNK inhibitors as anti-inflammatory and neuroprotective agents. Future Medicinal Chemistry 5:5, pages 539-551.
Crossref
Crossref
Stacy Van Epps, Bryan Fiamengo, Jeremy Edmunds, Anna Ericsson, Kristine Frank, Michael Friedman, Dawn George, Jonathan George, Eric Goedken, Brian Kotecki, Gloria Martinez, Philip Merta, Michael Morytko, Shashank Shekhar, Barbara Skinner, Kent Stewart, Jeffrey Voss, Grier Wallace, Lu Wang, Lu Wang & Neil Wishart. (2013) Design and synthesis of tricyclic cores for kinase inhibition. Bioorganic & Medicinal Chemistry Letters 23:3, pages 693-698.
Crossref
Crossref
Pradeep KumarSnehashish Banik. (2013) Pharmacotherapy Options in Rheumatoid Arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 6, pages CMAMD.S5558.
Crossref
Crossref
Kevin L. Winthrop. (2012) Infections and Biologic Therapy in Rheumatoid Arthritis. Rheumatic Disease Clinics of North America 38:4, pages 727-745.
Crossref
Crossref